NEW ASPECTS OF CLINICAL EFFECTIVENESS OF TYPE 5 PHOSPHOTIDYL ESTERASE INHIBITORS IN THE TREATMENT OF PATIENTS WITH ERECTILE DYSFUNCTION
- Authors: Gamidov S.I.1, Ovchinnikov R.I.1, Popova A.Y.1, Kramareva K.I.1, Hamidov SI1, Ovchinnikov RI1, Popova AY.1, Kramareva KI1
-
Affiliations:
- Issue: No 4 (2012)
- Pages: 42-46
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279364
- ID: 279364
Cite item
Full Text
Abstract
About the authors
Safar Israilovich Gamidov
Ruslan Igorevich Ovchinnikov
Alina Yur'evna Popova
Kseniya Il'inichna Kramareva
S I Hamidov
R I Ovchinnikov
A Yu Popova
K I Kramareva
References
- Francis SH, Corbin JD. Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Curr Urol Rep 2003;4:457-65.
- Rotella DP. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov 2002;1:674-82.
- Montorsi F, Salonia A, Briganti A, et al. Vardenafil for the treatment of erectile dysfunction: a critical review of the literature based on personal clinical experience. Eur Urol 2005;47:612-21.
- Nehra A, Grantmyre J, Nadel A, et al. Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy. J Urol 2005;173:2067-71
- Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:777-83.
- Wagner G, Fugl-Meyer KS, Fugl-Meyer AR. Impact of erectile dysfunction on quality of life: patient and partner perspectives. Int J Impot Res 2000;12(4):S144-46.
- Chevret M, Jaudinot E, Sullivan K, et al. Impact of erectile dysfunction (ED) on sexual life of female partners: assessment with the Index of Sexual Life (ISL) questionnaire. J Sex Marital Ther 2004;30:157-72.
- Fisher WA, Rosen RC, Eardley I, et al. Sexual experience of female partners of men with erectile dysfunction: the female experience of men's attitudes to life events and sexuality (FEMALES) study. J Sex Med 2005;2:675-84.
- Rosen RC, Fisher WA, Beneke M, Homering M, Evers T. The COUPLES-project: a pooled analysis of patient and partner treatment satisfaction scale (TSS) outcomes following vardenafil treatment. BJU Int 2007;99:849-59.
- Weiss P, Brody S. Women's partnered orgasm consistency is associated with greater duration of penile-vaginal intercourse but not of foreplay. J Sex Med 2009;6:135-41.
- Miller SA, Byers ES. Actual and desired duration of foreplay and intercourse: discordance and misperceptions within heterosexual couples. J Sex Res 2004;41:301-9.
- Rosenberg MT, Adams PL, McBride TA, et al. Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study. Int J Clin Pract 2009;63:27-34.
- Miner M, Gilderman L, Bailen J, et al. Vardenafil in men with stable statin therapy and dyslipidemia. J Sex Med 2008;5:1455-67.
- Мазо ЕБ, Гамидов СИ, Иремашвили ВВ, Гасанов РВ. Патогенез эректильной дисфункции при метаболическом синдроме // Вестник РАМН 2008. № 2. С. 21-6.
Supplementary files
![](/img/style/loading.gif)